Our Company

A Heritage of Improving Lives Through Innovation

History Timeline Top Banner
O

ur company’s legacy of innovation began in 1858, when our founders made it their mission to bring better health solutions to patients who needed them most. Today, we are continuing that tradition by using the latest science and technology to help improve lives through the research and development of new medicines for serious diseases.  See our timeline below for select historical events.

The Journey Begins

EA4C17
EDWARD ROBINSON SQUIBB

1845

EDWARD ROBINSON SQUIBB
EDWARD ROBINSON SQUIBB

Dr. Squibb graduates from Philadelphia’s Jefferson Medical College. He spends a decade as a surgeon in the U.S. Navy, an experience that impresses upon him the urgent need for high-quality, standardized medicines. 

1858

FIRST LABORATORY

Dr. Squibb rents a brownstone in Brooklyn, New York, for his new business and begins pharmaceutical manufacturing operations. In December, he is severely burned in an ether fire that nearly destroys his business.

1858

FIRST LABORATORY
FIRST LABORATORY

Dr. Squibb rents a brownstone in Brooklyn, New York, for his new business and begins pharmaceutical manufacturing operations. In December, he is severely burned in an ether fire that nearly destroys his business.

SQUIBB MEDICINE CHEST

1861–1865

SQUIBB MEDICINE CHEST
SQUIBB MEDICINE CHEST

During the Civil War, Squibb manufactures compact, portable chests for military surgeons that contain an array of medicines and equipment—from ether and morphine to bandages and sponges. Each chest costs about $100, the equivalent of several thousand dollars today. 

 

 

1879

DR. SQUIBB’S PROPOSAL FOR SAFE MEDICINE

Dr. Squibb presents a report to the New York State Medical Society, “Proposed Law to Prevent the Adulteration of Food and Medicine and to Create a State Board of Health.” Known as the Squibb Bill, it becomes law and serves as the basis for the Federal Pure Food and Drug Act of 1906. 

1879

DR. SQUIBB’S PROPOSAL FOR SAFE MEDICINE
DR. SQUIBB’S PROPOSAL FOR SAFE MEDICINE

Dr. Squibb presents a report to the New York State Medical Society, “Proposed Law to Prevent the Adulteration of Food and Medicine and to Create a State Board of Health.” Known as the Squibb Bill, it becomes law and serves as the basis for the Federal Pure Food and Drug Act of 1906. 

CLINTON PHARMACEUTICALS

1887

CLINTON PHARMACEUTICALS
CLINTON PHARMACEUTICALS

William Bristol and John Myers invest $5,000 to purchase the failing Clinton Pharmaceutical Company. With a pledge to sell no “quack remedies,” the two quickly turn the business around.

1892

E.R. SQUIBB & SONS FORMED

Dr. Squibb forms a partnership with his sons, Edward and Charles, and the firm is renamed E.R Squibb & Sons. The company has capital assets of $1.5 million, according to the Articles of Incorporation filed in 1895. 

1892

E.R. SQUIBB & SONS FORMED
E.R. SQUIBB & SONS FORMED

Dr. Squibb forms a partnership with his sons, Edward and Charles, and the firm is renamed E.R Squibb & Sons. The company has capital assets of $1.5 million, according to the Articles of Incorporation filed in 1895. 

FIRST BREAKTHROUGH PRODUCT

1898

FIRST BREAKTHROUGH PRODUCT

Marketed as a tonic and laxative, Sal Hepatica salts, dubbed the “poor man’s spa,” mimic the taste and effect of the natural mineral waters of a Bohemian spa. Within a decade, annual sales rise to a half-million dollars. The product is a mainstay of Bristol Myers until 1974. 

1898

FIRST BREAKTHROUGH PRODUCT
FIRST BREAKTHROUGH PRODUCT

Marketed as a tonic and laxative, Sal Hepatica salts, dubbed the “poor man’s spa,” mimic the taste and effect of the natural mineral waters of a Bohemian spa. Within a decade, annual sales rise to a half-million dollars. The product is a mainstay of Bristol Myers until 1974. 

BRISTOL, MYERS COMPANY

1899

BRISTOL, MYERS COMPANY
BRISTOL, MYERS COMPANY

Bristol and Myers rename their business the Bristol, Myers Company, which outgrows its home in Clinton, New York. The company relocates — first to Syracuse and then, in 1899, to Brooklyn to better serve customers in New England and Pennsylvania.

IPANA

1901

IPANA

Bristol Myers introduces Ipana toothpaste, featuring a disinfectant to prevent tooth decay and gum disease. 

1901

IPANA
IPANA

Bristol Myers introduces Ipana toothpaste, featuring a disinfectant to prevent tooth decay and gum disease. 

1902

SQUIBB QUALITY-CONTROL LABORATORY

E.R. Squibb & Sons establishes its first quality-control laboratory. Soon, it has nearly 100 employees and produces over 800 preparations. 

1902

SQUIBB QUALITY-CONTROL LABORATORY
SQUIBB QUALITY-CONTROL LABORATORY

E.R. Squibb & Sons establishes its first quality-control laboratory. Soon, it has nearly 100 employees and produces over 800 preparations. 

NEW JERSEY PLANT

1905

NEW JERSEY PLANT
NEW JERSEY PLANT

E.R. Squibb & Sons purchases an ether manufacturing plant in what was then the wilds of New Brunswick, New Jersey. 

1906

PURE FOOD AND DRUG ACT

President Theodore Roosevelt signs the Pure Food and Drug Act of 1906 into law. Although Dr. Squibb died in 1900, the act is a triumph of his lifelong crusade for safe, reliable pharmaceutical products. 

GROWING IN NEW JERSEY

Bristol Myers purchases seven acres in Hillside, New Jersey, for expanded production of Sal Hepatica. 

1906

PURE FOOD AND DRUG ACT
PURE FOOD AND DRUG ACT

President Theodore Roosevelt signs the Pure Food and Drug Act of 1906 into law. Although Dr. Squibb died in 1900, the act is a triumph of his lifelong crusade for safe, reliable pharmaceutical products. 

GROWING IN NEW JERSEY

Bristol Myers purchases seven acres in Hillside, New Jersey, for expanded production of Sal Hepatica. 

DIGITALIS

1917

DIGITALIS

E.R. Squibb & Sons pioneers the standardization of digitalis, derived from the foxglove plant as an early treatment for heart conditions.

1917

DIGITALIS
DIGITALIS

E.R. Squibb & Sons pioneers the standardization of digitalis, derived from the foxglove plant as an early treatment for heart conditions.

BRISTOL MYERS GOES PUBLIC

1929

BRISTOL MYERS GOES PUBLIC
BRISTOL MYERS GOES PUBLIC

Gross profits top $1 million and the company’s products are sold in 26 countries. Bristol Myers becomes a publicly held firm on the New York Stock Exchange. 

1938

SQUIBB INSTITUTE FOR MEDICAL RESEARCH

Squibb furthered its commitment to innovative research by opening the 52,000-square foot Squibb Institute for Medical Research in New Brunswick, New Jersey.

1938

SQUIBB INSTITUTE FOR MEDICAL RESEARCH
SQUIBB INSTITUTE FOR MEDICAL RESEARCH

Squibb furthered its commitment to innovative research by opening the 52,000-square foot Squibb Institute for Medical Research in New Brunswick, New Jersey.

INTOCOSTRIN

1939

INTOCOSTRIN

Squibb researchers develop a new method for preparing curare and provide free samples of Intocostrin to clinical researchers, who find the curare extract helpful in relaxing the muscles of surgical patients.

1939

INTOCOSTRIN
INTOCOSTRIN

Squibb researchers develop a new method for preparing curare and provide free samples of Intocostrin to clinical researchers, who find the curare extract helpful in relaxing the muscles of surgical patients.

CHEPLIN BIOLOGICAL LABORATORIES

1943

CHEPLIN BIOLOGICAL LABORATORIES
CHEPLIN BIOLOGICAL LABORATORIES 

Bristol Myers acquires Cheplin Laboratories in Syracuse, New York, enabling it to mass produce penicillin during World War II. This marks the company’s entry into ethical drug development. 

1944

PENICILLIN PRODUCTION PLANT

Squibb opens the world’s largest penicillin production facility in New Brunswick, New Jersey.

1944

PENICILLIN PRODUCTION PLANT
PENICILLIN PRODUCTION PLANT

Squibb opens the world’s largest penicillin production facility in New Brunswick, New Jersey.

FLO-CILLIN ‘96’

1948

FLO-CILLIN ‘96’

Bristol Laboratories introduces Flo-Cillin 96, a long-lasting injectable penicillin.

NEW PAIN RELIEVER

Bufferin is also introduced.

1948

FLO-CILLIN ‘96’
FLO-CILLIN ‘96’

Bristol Laboratories introduces Flo-Cillin 96, a long-lasting injectable penicillin.

NEW PAIN RELIEVER

Bufferin is also introduced.

SQUIBB RECEIVES THE LASKER AWARD

1955

SQUIBB RECEIVES THE LASKER AWARD

The company receives one of the most respected science prizes in the world for discovering anti-tubercular properties for an antibiotic used to treat tuberculosis.

1955

SQUIBB RECEIVES THE LASKER AWARD
SQUIBB RECEIVES THE LASKER AWARD

The company receives one of the most respected science prizes in the world for discovering anti-tubercular properties for an antibiotic used to treat tuberculosis.

EARLY CANCER RESEARCH

1956

EARLY CANCER RESEARCH
EARLY CANCER RESEARCH

Bristol Myers Squibb enters the cancer drug development field, building on collaborations around promising antibiotics with the Microbial Chemistry Research Foundation of Japan.

1959

CLAIROL PURCHASED

Bristol Myers acquires the hair-coloring company Clairol, which was founded in 1931 by Joan and Lawrence M. Gelb. Their son, Richard L. Gelb, would later serve as Bristol Myers’ president, CEO and Chairman of the Board.

1959

CLAIROL PURCHASED
CLAIROL PURCHASED

Bristol Myers acquires the hair-coloring company Clairol, which was founded in 1931 by Joan and Lawrence M. Gelb. Their son, Richard L. Gelb, would later serve as Bristol Myers’ president, CEO and Chairman of the Board.

NEW LABORATORY

1966

NEW LABORATORY
NEW LABORATORY

Ground is broken for the construction of Bristol Myers Products research and development laboratories in Hillside, New Jersey. It is the largest proprietary laboratory in the world.

1967

MEAD JOHNSON & COMPANY

Bristol Myers Squibb acquires Mead Johnson. At the time, Mead-Johnson produces the only comprehensive line of infant feeding needs.

1967

MEAD JOHNSON & COMPANY
MEAD JOHNSON & COMPANY

Bristol Myers Squibb acquires Mead Johnson. At the time, Mead-Johnson produces the only comprehensive line of infant feeding needs.

1967

Anti-Cancer Treatment

Squibb researchers develop the company’s first anti-cancer treatment. 

1967

Anti-Cancer Treatment

Squibb researchers develop the company’s first anti-cancer treatment. 

SQUIBB HEADQUARTERS ESTABLISHED

1971

SQUIBB HEADQUARTERS ESTABLISHED
SQUIBB HEADQUARTERS ESTABLISHED

Squibb establishes worldwide headquarters in Princeton, New Jersey, and expands facilities for the Squibb Institute for Medical Research. This allows Squibb to make more groundbreaking discoveries and advancements.

1972

PALOMAR PICTURES INTERNATIONAL

Bristol Myers announces the formation of Palomar Pictures International. Palomar produces several films, including The Stepford Wives and The Taking of Pelham One Two Three. The company exits the film business two years later.

1972

PALOMAR PICTURES INTERNATIONAL
PALOMAR PICTURES INTERNATIONAL

Bristol Myers announces the formation of Palomar Pictures International. Palomar produces several films, including The Stepford Wives and The Taking of Pelham One Two Three. The company exits the film business two years later.

1973

PRODUCT APPROVAL

FDA approves MUTAMYCIN® (mytomycin). 

1973

PRODUCT APPROVAL

FDA approves MUTAMYCIN® (mytomycin). 

1974

PRODUCT APPROVAL

FDA approves BLENOXANE® (bleomycin sulfate). 

1974

PRODUCT APPROVAL

FDA approves BLENOXANE® (bleomycin sulfate). 

1975

PRODUCT APPROVAL

FDA approves CAPOTEN® (captopril). 

1975

PRODUCT APPROVAL

FDA approves CAPOTEN® (captopril). 

1976

PRODUCT APPROVAL

FDA approves CeeNU® (lomustine) and BICNU® (carmustine). 

1976

PRODUCT APPROVAL

FDA approves CeeNU® (lomustine) and BICNU® (carmustine). 

CREATION OF CONVATEC

1978

CREATION OF CONVATEC
CREATION OF CONVATEC

ConvaTec is formed by Squibb to market ostomy and wound therapy products.

1979

PRODUCT APPROVAL

PLATINOL® (cisplatin) becomes the first platinum-containing anti-cancer drug for testicular cancer. 

1979

PRODUCT APPROVAL

PLATINOL® (cisplatin) becomes the first platinum-containing anti-cancer drug for testicular cancer. 

1983

PRODUCT APPROVAL

The FDA approves VEPESID® (etoposide). 

1983

PRODUCT APPROVAL

The FDA approves VEPESID® (etoposide). 

BRISTOL MYERS RESEARCH COMPLEX OPENS

1986

BRISTOL MYERS RESEARCH COMPLEX OPENS

Bristol Myers opens a state-of-the-art research complex in Wallingford, Connecticut, housing more than 800 scientists and support staff. In 1995, it is named the Richard L. Gelb Center for Pharmaceutical Research and Development after the former chairman and CEO. 

1986

BRISTOL MYERS RESEARCH COMPLEX OPENS
BRISTOL MYERS RESEARCH COMPLEX OPENS

Bristol Myers opens a state-of-the-art research complex in Wallingford, Connecticut, housing more than 800 scientists and support staff. In 1995, it is named the Richard L. Gelb Center for Pharmaceutical Research and Development after the former chairman and CEO. 

1986

PRODUCT APPROVAL

BUSPAR, discovered by Bristol Myers neuroscience researchers, is approved for the treatment of generalized anxiety disorder.

1986

PRODUCT APPROVAL

BUSPAR, discovered by Bristol Myers neuroscience researchers, is approved for the treatment of generalized anxiety disorder.

1989

BRISTOL MYERS AND SQUIBB MERGE

Bristol Myers merges with Squibb, creating a global leader in the health care industry. The merger creates Bristol Myers Squibb, the world’s second-largest pharmaceutical enterprise. One of the first medicines the new company introduces is PARAPLATIN, approved for treating recurrent ovarian cancer.

1989

BRISTOL MYERS AND SQUIBB MERGE
BRISTOL MYERS AND SQUIBB MERGE

Bristol Myers merges with Squibb, creating a global leader in the health care industry. The merger creates Bristol Myers Squibb, the world’s second-largest pharmaceutical enterprise. One of the first medicines the new company introduces is PARAPLATIN, approved for treating recurrent ovarian cancer.

BRISTOL MYERS SQUIBB FOUNDATION ESTABLISHED

1990

BRISTOL MYERS SQUIBB FOUNDATION ESTABLISHED
BRISTOL MYERS SQUIBB FOUNDATION ESTABLISHED

Inspired by the Bristol Myers Fund established in 1953, the Bristol Myers Squibb Foundation is created to promote health equity and improve health outcomes of populations disproportionately affected by serious diseases. Through its work around the globe, the Foundation focuses on strengthening health care worker capacity, integrating medical care and community-based supportive services, and mobilizing communities in the fight against disease.

1991

Product Approval

1991

Product Approval

1997

RESEARCH CAMPUS OPENS

Bristol Myers Squibb opens a 433-acre research campus in Hopewell, New Jersey.  

1997

RESEARCH CAMPUS OPENS
RESEARCH CAMPUS OPENS

Bristol Myers Squibb opens a 433-acre research campus in Hopewell, New Jersey.  

1997

PRODUCT APPROVAL 

1997

PRODUCT APPROVAL 
NATIONAL MEDAL OF TECHNOLOGY

1998

NATIONAL MEDAL OF TECHNOLOGY
NATIONAL MEDAL OF TECHNOLOGY

President Bill Clinton awards the National Medal of Technology — America’s highest honor for technological innovation — to Bristol Myers Squibb "for extending and enhancing human life through innovative pharmaceutical research and development, and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry." 

1999

SECURE THE FUTURE INITIATIVE ANNOUNCED

The Bristol Myers Squibb Foundation announces SECURE THE FUTURE®, a $100 million commitment to advance HIV/AIDS research and community outreach programs in seven African countries: Botswana, Namibia, Lesotho, Swaziland, Uganda, Burkina Faso and Tanzania. 

1999

SECURE THE FUTURE INITIATIVE ANNOUNCED
SECURE THE FUTURE INITIATIVE ANNOUNCED

The Bristol Myers Squibb Foundation announces SECURE THE FUTURE®, a $100 million commitment to advance HIV/AIDS research and community outreach programs in seven African countries: Botswana, Namibia, Lesotho, Swaziland, Uganda, Burkina Faso and Tanzania. 

CHILDREN’S HOSPITAL OPENS

2001

CHILDREN’S HOSPITAL OPENS
CHILDREN’S HOSPITAL OPENS

The Bristol Myers Squibb Children’s Hospital opens as part of Robert Wood Johnson University Hospital in New Brunswick, New Jersey. The first freestanding children’s hospital in the state, it offers care without regard to a family’s ability to pay and offers more than 45 pediatric specialties.

DUPONT PHARMACEUTICALS PURCHASED 

DuPont pharmaceuticals is acquired, strengthening Bristol Myers Squibb’s HIV and cardiovascular businesses while also adding medical imaging. 

2001

PRODUCT ACQUISITION   

2002

PRODUCT APPROVAL

FDA approves ABILIFY® (aripiprazole). 

2002

PRODUCT APPROVAL

FDA approves ABILIFY® (aripiprazole). 

2003

PRODUCT APPROVAL

FDA approves REYATAZ® (atazanavir).

2003

PRODUCT APPROVAL

2004

PRODUCT APPROVAL

FDA approves BARACLUDE® (entecavir).
U.S. Full Prescribing Information including Boxed WARNINGS  (PDF)

FDA approves ERBITUX® (cetuximab). 

2004

PRODUCT APPROVAL
CLINICAL CENTER FOR CHILDREN WITH HIV/AIDS

2007

CLINICAL CENTER FOR CHILDREN WITH HIV/AIDS OPENS

The clinical center at the Bristol Myers Squibb Children’s Hospital at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, is dedicated to the research and treatment of children’s immune system disorders and infectious diseases. The Bristol Myers Squibb Pediatric Infectious Disease and Immunology Center is made possible by a $5 million gift from the Bristol Myers Squibb Foundation.

2007

CLINICAL CENTER FOR CHILDREN WITH HIV/AIDS
CLINICAL CENTER FOR CHILDREN WITH HIV/AIDS OPENS

The clinical center at the Bristol Myers Squibb Children’s Hospital at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, is dedicated to the research and treatment of children’s immune system disorders and infectious diseases. The Bristol Myers Squibb Pediatric Infectious Disease and Immunology Center is made possible by a $5 million gift from the Bristol Myers Squibb Foundation.

2007

PRODUCT APPROVAL

FDA approves IXEMPRA® (ixabepilone).

2007

PRODUCT APPROVAL

FDA approves IXEMPRA® (ixabepilone).

2009

BRISTOL MYERS SQUIBB ACQUIRES MEDAREX

Bristol Myers Squibb acquires Medarex, Inc., a biotech company and a partner since 2005. The acquisition significantly expands the company’s oncology and immunology pipeline.

2009

BRISTOL MYERS SQUIBB ACQUIRES MEDAREX
BRISTOL MYERS SQUIBB ACQUIRES MEDAREX

Bristol Myers Squibb acquires Medarex, Inc., a biotech company and a partner since 2005. The acquisition significantly expands the company’s oncology and immunology pipeline.

2009

PRODUCT APPROVAL

FDA approves ONGLYZA® (saxagliptin).

2009

PRODUCT APPROVAL

FDA approves ONGLYZA® (saxagliptin).

2010

PRODUCT APPROVAL

FDA approves KOMBIGLYZE® XR (saxagliptin and metformin HCl extended‐release).

2010

PRODUCT APPROVAL

FDA approves KOMBIGLYZE® XR (saxagliptin and metformin HCl extended‐release).

INVESTING IN THE FUTURE

2013

INVESTING IN THE FUTURE
INVESTING IN THE FUTURE

To expand its capabilities in development and manufacturing of biologics, the company announces a $250 million expansion of its manufacturing complex in Devens, Massachusetts.

EXPANSION CONTINUES

2014

EXPANSION CONTINUES

Construction begins on a new, large-scale biologics manufacturing facility in Cruiserath, Ireland, to be built on the grounds of its existing bulk pharmaceutical manufacturing plant.

A new state-of-the-art office campus is planned for Lawrenceville, New Jersey, to replace leased facilities in Plainsboro and West Windsor. 

2014

EXPANSION CONTINUES
EXPANSION CONTINUES

Construction begins on a new, large-scale biologics manufacturing facility in Cruiserath, Ireland, to be built on the grounds of its existing bulk pharmaceutical manufacturing plant.

A new state-of-the-art office campus is planned for Lawrenceville, New Jersey, to replace leased facilities in Plainsboro and West Windsor. 

2014

Product Approval

FDA approves OPDIVO® (nivolumab).

2014

Product Approval

2015

BRISTOL MYERS SQUIBB NAMED A LEADING SUSTAINABLE COMPANY

Bristol Myers Squibb is recognized as one of Dow Jones’ North America Index of Leading Sustainable Companies. Its efforts to promote economic, social and environmental sustainability are core to the mission and reflect its ongoing commitment to patients, employees and partners, the environment and communities around the world.

Bristol Myers Squibb Foundation Celebrates 60th Anniversary 

The Bristol Myers Squibb Foundation marks a quarter of a century helping millions of people across the world overcome serious diseases. 

2015

BRISTOL MYERS SQUIBB NAMED A LEADING SUSTAINABLE COMPANY
BRISTOL MYERS SQUIBB NAMED A LEADING SUSTAINABLE COMPANY

Bristol Myers Squibb is recognized as one of Dow Jones’ North America Index of Leading Sustainable Companies. Its efforts to promote economic, social and environmental sustainability are core to the mission and reflect its ongoing commitment to patients, employees and partners, the environment and communities around the world.

Bristol Myers Squibb Foundation Celebrates 60th Anniversary 

The Bristol Myers Squibb Foundation marks a quarter of a century helping millions of people across the world overcome serious diseases. 

2015

PRODUCT APPROVAL

2015

PRODUCT APPROVAL
PRINCETON PIKE CAMPUS OPENS

2016

PRINCETON PIKE CAMPUS OPENS
PRINCETON PIKE CAMPUS OPENS

This state-of-the-art campus in New Jersey features work space designed to foster greater innovation, productivity and collaboration. 

PRIX GALIEN AWARD

Bristol Myers Squibb is awarded the Prix Galien U.S. “Discovery of the Decade.” This is the third Prix Galien honor that the company has received, after being recognized for “Best Biotechnology Product” in 2012 and “Best Biotechnology Product” in 2015. 

2017

BRISTOL MYERS SQUIBB CELEBRATES 130TH ANNIVERSARY 

Chairman and CEO Giovanni Caforio rings the New York Stock Exchange’s Closing Bell in celebration of the company milestone.

2017

BRISTOL MYERS SQUIBB CELEBRATES 130TH ANNIVERSARY
BRISTOL MYERS SQUIBB CELEBRATES 130TH ANNIVERSARY 

Chairman and CEO Giovanni Caforio rings the New York Stock Exchange’s Closing Bell in celebration of the company milestone.

BRISTOL MYERS SQUIBB ACQUIRES CELGENE

2019

BRISTOL MYERS SQUIBB ACQUIRES CELGENE

Bristol Myers Squibb and Celgene come together to create a leading biopharma company positioned to address the needs of patients with serious diseases.

2019

BRISTOL MYERS SQUIBB ACQUIRES CELGENE
BRISTOL MYERS SQUIBB ACQUIRES CELGENE

Bristol Myers Squibb and Celgene come together to create a leading biopharma company positioned to address the needs of patients with serious diseases.